Paysign, Inc. · NASDAQ:PAYS
Paysign — MicroCap Rodeo Spring Conference 2025
23 slides from Paysign's conference presentation, Jun 4, 2025
Slide 1: MicroCap Rodeo Spring Conference
NASDAQ: PAYS MicroCap Rodeo Spring Conference 6.04.2025
Slide 2: Important Notices: Forward-Looking Statements
Important Notices Forward-Looking Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Forward-Looking Statements”). All statements other t
Slide 3: Important Notices: Non-GAAP Financial Information
Important Notices Management’s Use of Non-GAAP Financial Information To supplement Paysign’s financial results presented on a GAAP basis, we use non-GAAP measures that exclude from net income the following cash and non-cash items: interest, taxes, depreciation and amortization and stock-based compen
Slide 4: Putting Payments Into Motion
Putting Payments Into Motion Paysign is a leading provider of integrated prepaid card programs and payment processing with advanced consumer engagement tools for customized, scalable solutions tailored to each client’s goals. Our innovative payment solutions are designed to support businesses across
Slide 5: Company Overview
Company Overview Paysign was incorporated in 1995 and is headquartered in southern Nevada. For more than 20 years, Paysign has been a trusted partner for major pharmaceutical and healthcare companies, as well as multinational corporations, delivering fully managed programs built to meet their indivi
Slide 6: Company Milestones
Company Milestones Company issued its first pharmaceutical prepaid assistance card. Company entered plasma donor compensation market. oY The company was listed on NASDAQ under the symbol “TPNL” Company rebranded as Paysign and commenced trading under the symbol “PAYS” Providing services to 480 plasm
Slide 7: Investment Highlights
Investment Highlights fo} LIS Financials Revenue Technol echnolo Growth gy strong cashflow, margin Fast growing, high-margin, Leading proprietary cloud- expansion, and zero debt profitable business with based payments platform predictable recurring revenues .! fit) Products and : Service and Leaders
Slide 8: Paysign at a Glance
Paysign at a Glance Stock price 6/2/2025 Market Cap Fully Diluted Shares Outstanding 2024 Annual Revenue TTM Revenue QI 2025 Gross Profit Margin 2024 Fully Diluted EPS TTM Fully Diluted EPS 2024 Fully Diluted Adjusted EBITDA per Stare TTM Fully Diluted Adjusted EBITDA per Share Cash (3/31/2025) Debt
Slide 9: 52-Week Stock Price Range
52-Week Stock Price Range Weekly Closing Price June 3, 2024, through June 2, 2025 $6.00 $5.32 $5.15 $5.00 $4.94 $4.79 $4.74 $4.55 $4.41 $4.43 $4.44$4.44 $4.45 $4.31 $4.17 $4.15 $4.07 $4.00 $3.87$3.94 $3.91 $3.95 $3.98 $3.86 $3.64$3.65 $3.71 $3.54 $3.61 $3.38 $3.46 $3.39 $3.38 $3.33 $3.18 $3.27 $2.99
Slide 10: Investment by the Numbers
Investment by the Numbers (| 2024 Revenue iq TTM Revenue TTM Adjusted EBITDA A QI 2025 Total Assets OU gss.am $63.8M $12.9M coll) §~= $205.1 Revenue by Segment © seams Aen ees Annual Revenue 00M ah oan som s40M $3803M som s2om L _ soos oot vos 202 2022 2028 2028 rm Revenue Drivers Cardholder Fees In
Slide 11: Patient Affordability Solutions
Patient Affordability Solutions Powering the Convergence of Fintech and Healthcare Pharmacy Benefit Copay Solutions: This includes the standard copay and voucher programs in the Pharmacy industry, which process claims using the the National Council for Prescription Drug Programs (NCPDP) transmission
Slide 12: Patient Affordability by the Numbers
Patient Affordability by the Numbers High growth business segment. Greater than 100% revenue growth expected in 2025. High-margin business. Pharma Revenue by Quarter Annual Pharma Revenue
Slide 13: Plasma Donor Solutions
Plasma Donor Solutions Powering the Convergence of Fintech and Healthcare Paysign offers donor compensation programs that give our clients the tools they need to streamline their operations while increasing donor retention. Since entering the plasma donor compensation market in 2011, Paysign has bec
Slide 14: Plasma by the Numbers
Plasma by the Numbers *COLLECTING PLASMA IN THE US: ECOSYSTEM ANALYSIS, COST BENCHMARKING & FORECAST TO 2034, Marketing Research Bureau, March 2025
Slide 15: Recent Developments
Recent Developments Acquisition of Gamma Innovation On March 25, 2025, Paysign announced that it acquired the assets of Gamma Innovation LLC (Gamma), significantly enhancing Paysign’s capabilities in plasma donor and pharmaceutical patient engagement technologies. Among the key assets acquired by Pa
Slide 16: New Markets Overview
New Markets Overview Additional Market Niches Leverage Paysign Solutions Paysign consistently builds and launches beta programs into niche markets to refine payments infrastructure, collect data, and analyze performance. Other growth strategies into additional markets include integrations, partnersh
Slide 17: 2026 U.S. Open-Loop Prepaid Market
2026 U.S. Open-Loop Prepaid Market Paysign Market Segments Paysign Products Paysign Premier Digital Bank Account Total Prepaid Market $266.7B (36.6%) Paysign GPR Card Financial Services (GPR) CAGR 6%, 2020-2026 Paysign Payroll Card $245.9B (33.7%) Paysign Healthcare Benefit Card Payroll & Benefits i
Slide 18: Financial Highlights
Financial Highlights Income Statement Summary
Slide 19: Analyst Coverage
Analyst Coverage Company Analyst Recommendation Price Target DA. Davidson & Company Peter Heckman $6.00 Ladenburg, Thalman & Co. Inc. Jonathan Hickman Strong Buy $8.25 Maxim Group. Michael Diana $7.00 iad NASDAQ: PAYS
Slide 20: Resources
Resources About Us - Donating Plasma Home - Marketing Research Bureau Home - Donating Plasma A white building with a flag on it Description automatically generated House Committee on Oversight and Accountability FTC Interim Report – Pharmacy Benefit Managers: Staff Report – The Role of Pharmacy Bene
Slide 21: Leadership Team
Leadership Team Mark Newcomer President & Chief Executive Officer Robert Strobo Chief Legal Officer & General Counsel Matt Turner President of Patient Affordability sf Jeff Baker Chief Financial Officer Brad Cunningham Chief Technology Officer Joan Herman EvP, EFT Operations Matt Lanford Chief Payme
Slide 22: Independent Directors
Independent Directors +Former CEO and President of Green Dot Corporation (NYSE: GDOT) +Former CEO of NetSpend (2008-2013); Grew annual revenue from $128M to $351M, with over 2.4 million cardholder accounts; NetSpend acquired by Total system Services: (NYSE: TSS) for $148 +Co-founder, former presiden
Slide 23: Thank you!
Main: 702.453.2221 Toll-Free: 888.522.4810 Investor Relations ir@paysign.com 2615 St. Rose Parkway Henderson, NV 89052 Thank you!